Innova Captab Limited (IN:INNOVACAP)
:INNOVACAP
Want to see IN:INNOVACAP full AI Analyst Report?
Top Page
Innova Captab Limited
(INNOVACAP)
Select Model
Select Model
Rating:68Neutral
Price Target:
₹724.00
▲(0.11% Upside)
Action:ReiteratedDate:12/10/25
Innova Captab Limited's overall stock score is driven by strong financial performance, particularly in revenue growth and profitability margins. However, technical indicators suggest bearish momentum, and the stock's high P/E ratio indicates potential overvaluation. Improving cash flow and monitoring technical trends are key for future performance.
Positive Factors
Robust revenue growth
Sustained ~25.6% revenue growth indicates durable demand and successful market penetration in finished dosages and CDMO services. Over 2-6 months this supports higher capacity utilisation, stronger contract leverage and a rising top line that can fund margin improvements and strategic investments.
Negative Factors
Weak cash conversion
OCF covering only half of reported net income signals that earnings are not fully converted to cash. Persistently weak cash conversion can constrain working capital, limit self-funded growth and raise reliance on external financing, posing a durable operational risk to liquidity and execution.
Read all positive and negative factors
Positive Factors
Negative Factors
Robust revenue growth
Sustained ~25.6% revenue growth indicates durable demand and successful market penetration in finished dosages and CDMO services. Over 2-6 months this supports higher capacity utilisation, stronger contract leverage and a rising top line that can fund margin improvements and strategic investments.
Read all positive factors
Innova Captab Limited (INNOVACAP) vs. iShares MSCI India ETF (INDA)
Market Cap
₹41.82B
Dividend YieldN/A
Average Volume (3M)1.70K
Price to Earnings (P/E)24.4
Beta (1Y)0.84
Revenue Growth25.63%
EPS Growth3.93%
CountryIN
Employees1,600
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)7.37
Shares Outstanding57,224,930
10 Day Avg. Volume1,138
30 Day Avg. Volume1,704
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)5.33
Price to Sales (P/S)4.11
P/FCF Ratio-47.03
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)33
Revenue Forecast (FY)₹19.25B
Innova Captab Limited Business Overview & Revenue Model
Company Description
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organ...
How the Company Makes Money
Innova Captab Limited generates revenue through multiple streams, primarily by selling its software solutions and analytics platforms to corporate clients on a subscription or licensing basis. The company also earns income from consulting services...
Innova Captab Limited Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.63B | 12.44B | 10.77B | 9.26B | 8.00B | 4.10B |
| Gross Profit | 4.38B | 4.30B | 3.42B | 2.35B | 1.73B | 611.45M |
| EBITDA | 2.08B | 1.86B | 1.67B | 1.23B | 987.68M | 558.57M |
| Net Income | 1.24B | 1.28B | 943.45M | 679.54M | 639.53M | 345.00M |
Balance Sheet | ||||||
| Total Assets | 16.92B | 15.80B | 13.21B | 10.19B | 5.75B | 3.70B |
| Cash, Cash Equivalents and Short-Term Investments | 584.35M | 652.81M | 840.92M | 70.25M | 8.75M | 47.95M |
| Total Debt | 3.36B | 3.38B | 2.45B | 2.37B | 1.99B | 454.97M |
| Total Liabilities | 6.71B | 6.21B | 4.90B | 6.93B | 3.67B | 2.25B |
| Stockholders Equity | 10.21B | 9.59B | 8.31B | 2.77B | 2.09B | 1.45B |
Cash Flow | ||||||
| Free Cash Flow | -125.34M | -1.09B | -1.41B | -118.67M | -209.85M | 228.33M |
| Operating Cash Flow | 297.19M | 638.44M | 1.46B | 671.24M | 588.98M | 415.66M |
| Investing Cash Flow | -354.74M | -1.52B | -4.99B | -908.43M | -1.88B | -196.68M |
| Financing Cash Flow | -92.25M | 915.33M | 3.61B | 270.92M | 1.25B | -193.36M |
Innova Captab Limited Technical Analysis
Positive
723.20
Price Trends
692.10
Positive
698.50
Positive
777.36
Negative
Market Momentum
8.45
Negative
62.70
Neutral
77.92
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:INNOVACAP, the sentiment is Positive. The current price of 723.2 is above the 20-day moving average (MA) of 696.73, above the 50-day MA of 692.10, and below the 200-day MA of 777.36, indicating a neutral trend. The MACD of 8.45 indicates Negative momentum. The RSI at 62.70 is Neutral, neither overbought nor oversold. The STOCH value of 77.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:INNOVACAP.
Innova Captab Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | ₹28.32B | 18.57 | ― | 0.28% | 7.19% | 82.31% | |
68 Neutral | ₹41.82B | 24.44 | ― | ― | 25.63% | 3.93% | |
61 Neutral | ₹26.35B | 2.94 | ― | ― | 18.18% | ― | |
57 Neutral | ₹28.85B | 67.80 | ― | 0.03% | 9.88% | -40.57% | |
57 Neutral | ₹22.91B | 20.54 | ― | 0.49% | 1.02% | -24.31% | |
54 Neutral | ₹30.95B | -76.20 | ― | ― | -10.02% | -82.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:INNOVACAP
Innova Captab Limited
730.75
-150.84
-17.11%
IN:BLISSGVS
Bliss Gvs Pharma Limited
267.75
149.39
126.21%
IN:GUFICBIO
Gufic Biosciences Limited
287.65
-78.85
-21.51%
IN:MOREPENLAB
Morepen Laboratories Limited
41.81
-18.25
-30.39%
IN:ORCHPHARMA
Orchid Pharma Limited
610.15
-195.55
-24.27%
IN:UNICHEMLAB
Unichem Laboratories Limited
374.25
-229.35
-38.00%
Innova Captab Limited Corporate Events
Innova Captab to Review Q3 FY26 Results and Consider Interim Dividend on 23 January
Jan 19, 2026
Innova Captab Limited has scheduled a board meeting on 23 January 2026 to consider and approve its unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, alongside a proposal for declaration...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.